Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study

Objectives There is a lack of large longitudinal studies of urate deposition measured by dual-energy CT (DECT) during urate lowering therapy (ULT) in people with gout. We explored longitudinal changes in DECT urate depositions during a treat-to-target strategy with ULT in gout. Methods Patients with a recent gout flare and serum-urate (sUA) >360 mu mol/l attended tight-control visits during escalating ULT. The treatment target was sUA <360 mu mol/l, and <300 mu mol/l if presence of tophi. A DECT scanner (General Electric Discovery CT750 HD) acquired data from bilateral forefeet and ankles at baseline and after one and two years. Images were scored in known order, using the semi-quantitative Bayat method, by one experienced radiologist who was blinded to serum urate and clinical data. Four regions were scored: the first metatarsophalangeal (MTP1) joint, the other joints of the toes, the ankles and midfeet, and all tendons in the feet and ankles. Results DECT was measured at baseline in 187 of 211 patients. The mean (S.d.) serum urate level (mu mol/l) decreased from 501 (80) at baseline to 311 (48) at 12 months, and 322 (67) at 24 months. DECT scores at all locations decreased during both the first and the second year (P vs baseline), both for patients achieving and not achieving the sUA treatment target. Conclusions In patients with gout, urate depositions in ankles and feet as measured by DECT decreased both in the first and the second year, when patients were treated using a treat-to-target ULT strategy.

Automated summary

This study found that dual-energy CT measurements showed a decrease in urate depositions in ankles and feet in patients with gout during the first and second year of treat-to-target ULT strategy. This indicates the effectiveness of ULT in reducing urate deposition.